SuicideCAMPUSNCT04707066

Comprehensive Adaptive Multisite Prevention of University Student Suicide

A study testing Treatment As Usual (TAU), Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1 and Dialectical Behavior Therapy (DBT) - Phase 2 in people with Suicide, run by Duke University at 4 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 to 25 years
Conditions the study is for: Suicide
What is being tested?: Treatment As Usual (TAU), Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1 and Dialectical Behavior Therapy (DBT) - Phase 2
Type of treatment: Lifestyle or therapy programme
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 253 participants
Where: 4 sitesUnited States
Study dates: 25 Oct 2022to 19 Nov 2024
Phase: Interventional
Are there results?: Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 25 years
All sexes
No healthy volunteers
Adult

Who may be able to join

Enrolled at the university;
18 to 25 years of age;
Moderate to severe SI over the last two weeks indicated by a score of ³2 on the Counseling Center Assessment of Psychological Symptoms (CCAPS-34) question, "I have thoughts of ending my life" (range is 0 "not at all like me" to 4 "extremely like me"); and
Agree to video recording of all therapy and assessment sessions.

Who cannot join

Students who are deemed clinically inappropriate to receive services at the CCC by an intake counselor because of imminent risk, severe psychosis, or inability to remain enrolled in school (e.g., academic failure);
Students being unable to remain on campus long enough to go through the minimum number of sessions for Stage 1 (4 sessions);
Students who have received services at the CCC within the last three months (i.e., ATSs must be based on a new treatment episode).

Trial locations and contacts

4 sites in 1 country.

United States4 sites

Duke University
Durham, North Carolina, 27705
University of Oregon
Eugene, Oregon, 97403
Rutgers University
New Brunswick, New Jersey, 08901
University of Nevada - Reno
Reno, Nevada, 89557

Other trials in United States

About this study

Official title: Comprehensive Adaptive Multisite Prevention of University Student Suicide (CAMPUS): A Multisite Trial With Duke as a Site, and Duke as Single IRB of Record

Suicide is the 2nd leading cause of death among college students and suicidal ideation and suicide-related behaviors are a frequent presenting problem at college counseling centers (CCCs), which are overburdened. Studies show that some students respond rapidly to treatment, whereas others require considerably more resources. Evidence-based adaptive treatment strategies (ATSs) are needed to address this heterogeneity in responsivity and complexity. ATSs individualize treatment via decision rules specifying how the type and intensity of an intervention can be sequenced based on risk factors, response, or compliance.

The purpose of this multisite study is to investigate the effectiveness of four adaptive treatment strategies (ATSs) to treat college students who report suicidal ideation when first seeking services at their college counseling center

This multisite study will enroll moderately to severely suicidal college students in the "emerging adulthood" phase (ages 18-25) seeking services at CCCs. This Sequential Multi-Assignment Randomized Trial (SMART) will have two stages of intervention. In Stage 1, 700 participants from four CCCs will be randomized to 4-8 weeks of: 1) a suicide-focused treatment - Collaborative Assessment and Management of Suicidality (CAMS) or 2) Treatment as Usual (TAU). Sufficient responders to either intervention will discontinue services/be stepped down. Non-responders will be re-randomized to one of two Stage 2 higher intensity/dosage intervention options for an additional 4-16 weeks: 1) CAMS (either continued or administered for the first time) or 2) Comprehensive Dialectical Behavior Therapy (DBT), which includes individual therapy, skills group, and phone/text coaching for the clients and peer consultation for the counselors.

Read the detailed description

This study will utilize a Sequential Multi-Assignment Randomized Trial (SMART) design. College students seeking counseling services through the College Counseling Centers (CCCs) will be recruited.

In Stage 1, student participants will be initially randomized into either treatment as usual (TAU) or Collaborative Assessment and Management of Suicidality (CAMS). Student participants receiving TAU will receive the customary treatment they would receive at the CCC at a frequency typical to the site (e.g., once a week). Student participants receiving the CAMS intervention will receive CAMS through weekly sessions with a counselor that will last for 50-60 minutes.

Responders to either CAMS or TAU may stop intervention after three consecutive weeks of non-engagement in suicidal acts combined with the ability to cope with suicidal ideation, if present, based on counselor's clinical global impression ratings of improvement and severity. Stage 1 has an intended duration of between 4 and 8 weeks.

Non-responders to Stage 1 treatments, will be re-randomized to one of two Stage 2 treatments: CAMS or Dialectical Behavior Therapy (DBT). Student participants receiving DBT will engage in individual therapy and a skills training group. Stage 2 has an intended treatment duration between 4 and 16 weeks.

All treatment in Stage 1 and Stage 2 (TAU, CAMS, and DBT) will usually be administered in person.

Counselors will provide TAU, CAMS, and DBT to study participants. They will also participate in CAMS and DBT trainings and ongoing consultation teams for each.

The project estimates 36 months (3 years) total duration from beginning of recruitment until final data collection.

The duration of treatment will vary from 4 to 24 weeks and is based on response. Total participant duration in study, due to the assessments, is approximately 48 weeks (which includes the 24-week follow-up assessment).

Counselor participants will participate for 1-3 years.

Conditions: Suicide
Being tested: Treatment As Usual (TAU), Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1, Dialectical Behavior Therapy (DBT) - Phase 2, Maintenance/Monitoring - Phase 2, Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2
Keywords: Dialectical Behavior Therapy (DBT), Collaborative Assessment and Management of Suicide (CAMS), Sequential, multiple assignment, randomized trials (SMART), University Students
Medical subject headings: Suicide

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Treatment As Usual (TAU)Behavioural
Also called TAU - Phase 1
Treatment As Usual
Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1Behavioural
Also called CAMS
Collaborative Assessment and Management of Suicidality
Dialectical Behavior Therapy (DBT) - Phase 2Behavioural
Dialectical Behavior Therapy
Maintenance/Monitoring - Phase 2Behavioural
Maintenance/Monitoring
Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2Behavioural
Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2

Study groups in NCT04707066
Study group	Role	What they receive
1	Experimental	Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Responder, thus placed into ongoing Maintenance/Monitoring. Receives: Behavioral: Treatment As Usual (TAU); Behavioral: Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2
2	Experimental	Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 CAMS. Receives: Behavioral: Treatment As Usual (TAU); Behavioral: Dialectical Behavior Therapy (DBT) - Phase 2
3	Experimental	Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 DBT. Receives: Behavioral: Treatment As Usual (TAU); Behavioral: Maintenance/Monitoring - Phase 2
4	Experimental	Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Responder, thus placed into ongoing Maintenance/Monitoring. Receives: Behavioral: Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1; Behavioral: Dialectical Behavior Therapy (DBT) - Phase 2
5	Experimental	Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 CAMS. Receives: Behavioral: Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1; Behavioral: Maintenance/Monitoring - Phase 2
6	Experimental	Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 DBT. Receives: Behavioral: Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1; Behavioral: Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2

What is being measured

The primary outcome is the main question the study is designed to answer.

Suicide Ideation - Phase 1
Change in score of CAMS Scale for Suicidal Ideation (SSI). This is a 19 question measure, each rated from 0-2. Total score is from 0-38, with a higher score indicating greater suicidality concern.
Measured: Baseline to the end of Phase 1 treatment (up to 6 weeks)
Suicide Ideation - Phase 2
Change in score of CAMS Scale for Suicidal Ideation (SSI). This is a 19 question measure, each rated from 0-2. Total score is from 0-38, with a higher score indicating greater suicidality concern.
Measured: Baseline to the end of Stage 2 treatment (up to 14 weeks)
Suicide Ideation - Follow-up (Week 26)
Change in score of Scale for Suicidal Ideation (SSI). This is a 19 question measure, each item rated from 0-2. Total score is from 0-38, with a higher score indicating greater suicidality concern.
Measured: Baseline to the end of follow-up (up to 26 weeks)
Total Occurrences of Self-Reported Non-Suicidal Self Injury (NSSI) on the Self-Injurious Thoughts and Behaviors Interview (SITBI) - Phase 1
Count is based on SITBI NSSI section, item 15 "How many episodes since the last assessment have you hurt yourself without wanting to die?" completed by the independent evaluators.
Measured: From baseline to the end of Phase 1 (up to 6 weeks)
Total Occurrences of Self-Reported Non-Suicidal Self Injury (NSSI) on the Self-Injurious Thoughts and Behaviors Interview (SITBI) - Phase 2
Count is based on SITBI NSSI section, item 15 "How many episodes since the last assessment have you hurt yourself without wanting to die?" completed by the independent evaluators.
Measured: From baseline to the end of Phase 2 (up to 14 weeks)
Total Occurrences of Self-Reported Non-Suicidal Self Injury (NSSI) on the Self-Injurious Thoughts and Behaviors Interview (SITBI) - Follow-up
Count is based on SITBI NSSI section, item 15 "How many episodes since the last assessment have you hurt yourself without wanting to die?" completed by the independent evaluators.
Measured: From baseline to the end of follow-up (up to 26 weeks)
Total Occurrences of Suicide Attempt on the Self-Injurious Thoughts and Behaviors Interview (SITBI) - Phase 1
Count is based on SITBI suicide attempt section, items 1 and 6. Item 6 asks "Since the last assessment, have you tried to kill yourself? In other words, have you purposefully hurt yourself with some intent to die?" If they answered yes, then item 6 is asked "How many suicide attempts have you made since the last assessment?" by the independent evaluators.
Measured: From baseline to the end of Phase 1 (up to 6 weeks)
Total Occurrences of Suicide Attempt on the Self-Injurious Thoughts and Behaviors Interview (SITBI) - Phase 2
Count is based on SITBI suicide attempt section, items 1 and 6. Item 6 asks "Since the last assessment, have you tried to kill yourself? In other words, have you purposefully hurt yourself with some intent to die?" If they answered yes, then item 6 is asked "How many suicide attempts have you made since the last assessment?" by the independent evaluators.
Measured: From baseline to the end of Phase 2 (up to 14 weeks)
Total Occurrences of Suicide Attempt on the Self-Injurious Thoughts and Behaviors Interview (SITBI) - Follow-up
Count is based on SITBI suicide attempt section, items 1 and 6. Item 6 asks "Since the last assessment, have you tried to kill yourself? In other words, have you purposefully hurt yourself with some intent to die?" If they answered yes, then item 6 is asked "How many suicide attempts have you made since the last assessment?" by the independent evaluators.
Measured: From baseline to the end of follow-up (up to 26 weeks)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

25 Oct 202219 Nov 2024

First posted13 Jan 2021
Study start25 Oct 2022
Primary completion19 Nov 2024
Study completion19 Nov 2024

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
Publications (1)Papers the sponsor has linked to this study.
Other trials for SuicideStudies of the same condition, open and under way.
More trials run by Duke UniversityThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Prevention
Allocation: Randomised
Intervention model: Sequential
Model description: Sequential, multiple assignment, randomized trials (SMART) design
Masking: Single blind
Who is masked: Outcomes assessor
Enrolment: 253 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT04707066
Sponsor's protocol ID: Pro00103346
Other IDs: Pro00104815, R01MH116062, R01MH116052, R01MH116050, R01MH116061
Acronym: CAMPUS
Status last verified: Jul 2026
First submitted: 11 Jan 2021
Last updated: 19 Aug 2026
Results posted: Yes, on ClinicalTrials.gov
Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Yes: We will participant de-identified data (linked only by GUID) with the National Institute of Mental Health Data Archive (NDA). The NDA is an informatics system and research data repository developed by the National Institutes of Health (NIH) to share research data. The NDA provides the infrastructure to store, search across, and analyze various types of data. In addition, The NDA provides longitudinal storage of a research participant's information generated by one or more research studies. In other words, the NDA is able to associate a single research participant's genomic, imaging, clinical assessment and other information even if the data were collected at different locations or through different studies. By doing so, the NDA gives researchers access to more data than they can collect on their own, making it easier and faster for researchers to gather, evaluate, and share research information from a variety of sources.

Publications

Blalock K, Pistorello J, Rizvi SL, Seeley JR, Kassing F, Sinclair J, Oshin LA, Gallop RJ, Fry CM, Snyderman T, Jobes DA, Crumlish J, Krall HR, Stadelman S, Gozenman-Sapin F, Davies K, Steele D, Goldston DB, Compton SN. The Comprehensive Adaptive Multisite Prevention of University Student Suicide Trial: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2025 Apr 22;14:e68441. doi: 10.2196/68441.
PubMed 40262131

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Not yet recruiting
A Pre-post Study of a Lethal Means Safety Planning Intervention for Youth at Elevated Suicide Risk in the Emergency Department
Suicidal Ideas, Suicidal Ideation
RecruitingObservational study
Student Precarity and Psychiatry
Depressive Disorder, Major, Generalized Anxiety Disorder
Not yet recruiting
SERENE Low-Intensity Focused Ultrasound for Cognitive Control
Suicidal Ideation, Cognitive Control
Not yet recruiting
A MRT to Optimize a JITAI for Alcohol Craving and Suicide Ideation
Alcohol Use Disorder (AUD), Suicide Ideation
Enrolling by invitation
Pilot Study of a Modified Safety Planning Intervention for Elementary School-Aged Children - Main Study
Suicidal Ideation, Suicidal Behaviors

All Suicide trials

Study at a glance

From the registry record, last updated by the sponsor on 19 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Comprehensive Adaptive Multisite Prevention of University Student Suicide (CAMPUS): A Multisite Trial With Duke as a Site, and Duke as Single IRB of Record
ClinicalTrials.gov ID: NCT04707066
Acronym / sponsor ID: CAMPUS / Pro00103346
Conditions: Suicide
Keywords: Dialectical Behavior Therapy (DBT), Collaborative Assessment and Management of Suicide (CAMS), Sequential, multiple assignment, randomized trials (SMART), University Students
Study type: Interventional
Recruitment status: Completed
Enrolment: 253 participants (actual)
Lead sponsor: Duke UniversityUniversity, hospital or other
Collaborators: National Institute of Mental Health (NIMH)
Study start: 25 Oct 2022 (actual)
Primary completion: 19 Nov 2024 (actual)
Study completion: 19 Nov 2024 (actual)
First posted: 13 Jan 2021 (actual)
Results: Posted 19 Aug 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Detailed description

This study will utilize a Sequential Multi-Assignment Randomized Trial (SMART) design. College students seeking counseling services through the College Counseling Centers (CCCs) will be recruited.

All treatment in Stage 1 and Stage 2 (TAU, CAMS, and DBT) will usually be administered in person.

Counselors will provide TAU, CAMS, and DBT to study participants. They will also participate in CAMS and DBT trainings and ongoing consultation teams for each.

The project estimates 36 months (3 years) total duration from beginning of recruitment until final data collection.

Counselor participants will participate for 1-3 years.

Study design

Primary purpose: Prevention
Allocation: Randomised
Intervention model: Sequential
Masking: Single blind (outcomes assessor)
Number of arms: 6
Model description: Sequential, multiple assignment, randomized trials (SMART) design

Arm	Type	Receives
1	Experimental	Behavioral: Treatment As Usual (TAU), Behavioral: Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Responder, thus placed into ongoing Maintenance/Monitoring.
2	Experimental	Behavioral: Treatment As Usual (TAU), Behavioral: Dialectical Behavior Therapy (DBT) - Phase 2Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 CAMS.
3	Experimental	Behavioral: Treatment As Usual (TAU), Behavioral: Maintenance/Monitoring - Phase 2Subject assigned to CAMS for Phase 1. Subject is a Phase 1 CAMS Insufficient Responder, then assigned to Phase 2 DBT.
4	Experimental	Behavioral: Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1, Behavioral: Dialectical Behavior Therapy (DBT) - Phase 2Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Responder, thus placed into ongoing Maintenance/Monitoring.
5	Experimental	Behavioral: Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1, Behavioral: Maintenance/Monitoring - Phase 2Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 CAMS.
6	Experimental	Behavioral: Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1, Behavioral: Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2Subject assigned to TAU for Phase 1. Subject is a Phase 1 TAU Insufficient Responder, then assigned to Phase 2 DBT.

Who may qualify

Ages: 18 to 25 years
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult

Key inclusion criteria (4 listed)

Enrolled at the university;
18 to 25 years of age;
Moderate to severe SI over the last two weeks indicated by a score of ³2 on the Counseling Center Assessment of Psychological Symptoms (CCAPS-34) question, "I have thoughts of ending my life" (range is 0 "not at all like me" to 4 "extremely like me"); and
Agree to video recording of all therapy and assessment sessions.

Key exclusion criteria (3 listed)

Students who are deemed clinically inappropriate to receive services at the CCC by an intake counselor because of imminent risk, severe psychosis, or inability to remain enrolled in school (e.g., academic failure);
Students being unable to remain on campus long enough to go through the minimum number of sessions for Stage 1 (4 sessions);
Students who have received services at the CCC within the last three months (i.e., ATSs must be based on a new treatment episode).

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Treatment As Usual (TAU)Also: TAU - Phase 1Treatment As Usual	Behavioural	1, 2, 3
Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1Also: CAMSCollaborative Assessment and Management of Suicidality	Behavioural	4, 5, 6
Dialectical Behavior Therapy (DBT) - Phase 2Dialectical Behavior Therapy	Behavioural	2, 4
Maintenance/Monitoring - Phase 2Maintenance/Monitoring	Behavioural	3, 5
Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2Collaborative Assessment and Management of Suicidality (CAMS) - Phase 2	Behavioural	1, 6

Primary outcome

Suicide Ideation - Phase 1
Time frame: Baseline to the end of Phase 1 treatment (up to 6 weeks)
Change in score of CAMS Scale for Suicidal Ideation (SSI). This is a 19 question measure, each rated from 0-2. Total score is from 0-38, with a higher score indicating greater suicidality concern.
Suicide Ideation - Phase 2
Time frame: Baseline to the end of Stage 2 treatment (up to 14 weeks)
Change in score of CAMS Scale for Suicidal Ideation (SSI). This is a 19 question measure, each rated from 0-2. Total score is from 0-38, with a higher score indicating greater suicidality concern.
Suicide Ideation - Follow-up (Week 26)
Time frame: Baseline to the end of follow-up (up to 26 weeks)
Change in score of Scale for Suicidal Ideation (SSI). This is a 19 question measure, each item rated from 0-2. Total score is from 0-38, with a higher score indicating greater suicidality concern.
Total Occurrences of Self-Reported Non-Suicidal Self Injury (NSSI) on the Self-Injurious Thoughts and Behaviors Interview (SITBI) - Phase 1
Time frame: From baseline to the end of Phase 1 (up to 6 weeks)
Count is based on SITBI NSSI section, item 15 "How many episodes since the last assessment have you hurt yourself without wanting to die?" completed by the independent evaluators.
Total Occurrences of Self-Reported Non-Suicidal Self Injury (NSSI) on the Self-Injurious Thoughts and Behaviors Interview (SITBI) - Phase 2
Time frame: From baseline to the end of Phase 2 (up to 14 weeks)
Count is based on SITBI NSSI section, item 15 "How many episodes since the last assessment have you hurt yourself without wanting to die?" completed by the independent evaluators.
Total Occurrences of Self-Reported Non-Suicidal Self Injury (NSSI) on the Self-Injurious Thoughts and Behaviors Interview (SITBI) - Follow-up
Time frame: From baseline to the end of follow-up (up to 26 weeks)
Count is based on SITBI NSSI section, item 15 "How many episodes since the last assessment have you hurt yourself without wanting to die?" completed by the independent evaluators.
Total Occurrences of Suicide Attempt on the Self-Injurious Thoughts and Behaviors Interview (SITBI) - Phase 1
Time frame: From baseline to the end of Phase 1 (up to 6 weeks)
Count is based on SITBI suicide attempt section, items 1 and 6. Item 6 asks "Since the last assessment, have you tried to kill yourself? In other words, have you purposefully hurt yourself with some intent to die?" If they answered yes, then item 6 is asked "How many suicide attempts have you made since the last assessment?" by the independent evaluators.
Total Occurrences of Suicide Attempt on the Self-Injurious Thoughts and Behaviors Interview (SITBI) - Phase 2
Time frame: From baseline to the end of Phase 2 (up to 14 weeks)
Count is based on SITBI suicide attempt section, items 1 and 6. Item 6 asks "Since the last assessment, have you tried to kill yourself? In other words, have you purposefully hurt yourself with some intent to die?" If they answered yes, then item 6 is asked "How many suicide attempts have you made since the last assessment?" by the independent evaluators.
Total Occurrences of Suicide Attempt on the Self-Injurious Thoughts and Behaviors Interview (SITBI) - Follow-up
Time frame: From baseline to the end of follow-up (up to 26 weeks)
Count is based on SITBI suicide attempt section, items 1 and 6. Item 6 asks "Since the last assessment, have you tried to kill yourself? In other words, have you purposefully hurt yourself with some intent to die?" If they answered yes, then item 6 is asked "How many suicide attempts have you made since the last assessment?" by the independent evaluators.

Results and safety

Results posted to the registry on 19 Aug 2026, as reported by the sponsor. Figures are copied from the record, not re-analysed. Full results on ClinicalTrials.gov.

Participant flow

Group	Started	Completed
Phase 1 CAMS Responder, Ongoing Maintenance/Monitoring	47	40
Phase 1 CAMS Insufficient Responder, Phase 2 CAMS	30	15
Phase 1 CAMS Insufficient Responder, Phase 2 DBT	36	20
Phase 1 TAU Responder, Ongoing Maintenance/Monitoring	40	32
Phase 1 TAU Insufficient Responder, Phase 2 CAMS	36	26
Phase 1 TAU Insufficient Responder, Phase 2 DBT	38	17
College Counseling Centers (CCC) Counselors	26	23

Primary outcome: Suicide Ideation - Phase 1

Time frame: Baseline to the end of Phase 1 treatment (up to 6 weeks). Mean (Standard Deviation). Unit: score on a scale

Measure	Phase 1 CAMS Responder, Ongoing Maintenance/Monitoring n = 44	Phase 1 CAMS Insufficient Responder, Phase 2 CAMS n = 22	Phase 1 CAMS Insufficient Responder, Phase 2 DBT n = 29	Phase 1 TAU Responder, Ongoing Maintenance/Monitoring n = 38	Phase 1 TAU Insufficient Responder, Phase 2 CAMS n = 35	Phase 1 TAU Insufficient Responder, Phase 2 DBT n = 31	College Counseling Center (CCC) Counselors n = 0
Value	-7.59 (7.44)	-3.05 (5.79)	-3.72 (6.86)	-8.21 (8.55)	-2.89 (6.52)	-5.32 (8.10)	–

Population analysed: Participants with data collected at both baseline and end of Phase 1 (week 6). Data not collected on CCC Counselors.

Primary outcome: Suicide Ideation - Phase 2

Time frame: Baseline to the end of Stage 2 treatment (up to 14 weeks). Mean (Standard Deviation). Unit: score on a scale

Measure	Phase 1 CAMS Responder, Ongoing Maintenance/Monitoring n = 41	Phase 1 CAMS Insufficient Responder, Phase 2 CAMS n = 21	Phase 1 CAMS Insufficient Responder, Phase 2 DBT n = 26	Phase 1 TAU Responder, Ongoing Maintenance/Monitoring n = 33	Phase 1 TAU Insufficient Responder, Phase 2 CAMS n = 32	Phase 1 TAU Insufficient Responder, Phase 2 DBT n = 27	College Counseling Centers (CCC) Counselors n = 0
Value	-8.44 (6.43)	-8.19 (8.20)	-5.19 (7.44)	-10.27 (6.16)	-9.34 (7.61)	-8.44 (6.81)	–

Population analysed: Participants with data collected at both baseline and end of Phase 2 (week 14). Data not collected on CCC Counselors.

Primary outcome: Suicide Ideation - Follow-up (Week 26)

Time frame: Baseline to the end of follow-up (up to 26 weeks). Mean (Standard Deviation). Unit: score on a scale

Measure	Phase 1 CAMS Responder, Ongoing Maintenance/Monitoring n = 40	Phase 1 CAMS Insufficient Responder, Phase 2 CAMS n = 19	Phase 1 CAMS Insufficient Responder, Phase 2 DBT n = 24	Phase 1 TAU Responder, Ongoing Maintenance/Monitoring n = 32	Phase 1 TAU Insufficient Responder, Phase 2 CAMS n = 30	Phase 1 TAU Insufficient Responder, Phase 2 DBT n = 24	College Counseling Centers (CCC) Counselors n = 0
Value	-8.07 (7.43)	-6.95 (8.53)	-8.83 (8.72)	-9.66 (7.00)	-9.67 (8.66)	-9.79 (9.26)	–

Population analysed: Participants with data collected at both baseline and end of follow-up (week 26). Data not collected on CCC Counselors.

Primary outcome: Total Occurrences of Self-Reported Non-Suicidal Self Injury (NSSI) on the Self-Injurious Thoughts and Behaviors Interview (SITBI) - Phase 1

Time frame: From baseline to the end of Phase 1 (up to 6 weeks). Number. Unit: self-reported NSSIs

Measure	Phase 1 CAMS Responder, Ongoing Maintenance/Monitoring n = 11	Phase 1 CAMS Insufficient Responder, Phase 2 CAMS n = 14	Phase 1 CAMS Insufficient Responder, Phase 2 DBT n = 10	Phase 1 TAU Responder, Ongoing Maintenance/Monitoring n = 19	Phase 1 TAU Insufficient Responder, Phase 2 CAMS n = 13	Phase 1 TAU Insufficient Responder, Phase 2 DBT n = 16	College Counseling Centers (CCC) Counselors n = 0
Value	247	90	249	45	188	125	–

Population analysed: Participants with data collected and at least 1 NSSI reported at the end of Phase 1 (6 weeks). Data not collected on CCC Counselors.

Adverse events

Time frame: Up to 26 weeks. Other adverse events reported at 0% frequency or more

Group	Serious adverse events	Other adverse events	Deaths
Phase 1 Collaborative Assessment and Management of Suicidality (CAMS)	4 of 113 (3.5%)	5 of 113 (4.4%)	0 of 113
Phase 1 Treatment As Usual (TAU)	8 of 114 (7%)	7 of 114 (6.1%)	0 of 114
Phase 2 CAMS Maintenance Only	5 of 47 (10.6%)	6 of 47 (12.8%)	0 of 47
Phase 2 TAU Maintenance Only	8 of 40 (20%)	4 of 40 (10%)	0 of 40
Phase 2 CAMS	4 of 66 (6.1%)	6 of 66 (9.1%)	0 of 66
Phase 2 Dialectical Behavior Therapy (DBT)	10 of 74 (13.5%)	9 of 74 (12.2%)	0 of 74
College Counseling Center (CCC) Counselors	0 of 0	0 of 0	0

Loading the posted results from ClinicalTrials.gov…

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 19 Aug 2026.
Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Derived from this study: PubMed 40262131Blalock K, Pistorello J, Rizvi SL, Seeley JR, Kassing F, Sinclair J, Oshin LA, Gallop RJ, Fry CM, Snyderman T, Jobes DA, Crumlish J, Krall HR, Stadelman S, Gozenman-Sapin F, Davies K, Steele D, Goldston DB, Compton SN. The Comprehensive Adaptive Multisite Prevention of University Student Suicide Trial: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2025 Apr 22;14:e68441. doi: 10.2196/68441.
Individual participant dataSharing planned: Yes. We will participant de-identified data (linked only by GUID) with the National Institute of Mental Health Data Archive (NDA). The NDA is an informatics system and research data repository developed by the National Institutes of Health (NIH) to share research data. The NDA provides the infrastructure to store, search across, and analyze various types of data. In addition, The NDA provides longitudinal storage of a research participant's information generated by one or more research studies. In other words, the NDA is able to associate a single research participant's genomic, imaging, clinical assessment and other information even if the data were collected at different locations or through different studies. By doing so, the NDA gives researchers access to more data than they can collect on their own, making it easier and faster for researchers to gather, evaluate, and share research information from a variety of sources.

Related trials for Suicide

Not yet recruiting
A Pre-post Study of a Lethal Means Safety Planning Intervention for Youth at Elevated Suicide Risk in the Emergency Department
Suicidal Ideas, Suicidal Ideation
RecruitingObservational study
Student Precarity and Psychiatry
Depressive Disorder, Major, Generalized Anxiety Disorder
Not yet recruiting
SERENE Low-Intensity Focused Ultrasound for Cognitive Control
Suicidal Ideation, Cognitive Control
Not yet recruiting
A MRT to Optimize a JITAI for Alcohol Craving and Suicide Ideation
Alcohol Use Disorder (AUD), Suicide Ideation
Enrolling by invitation
Pilot Study of a Modified Safety Planning Intervention for Elementary School-Aged Children - Main Study
Suicidal Ideation, Suicidal Behaviors

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Scott Compton, PhD principal investigator

Duke University

Jacqueline Pistorello, PhD principal investigator

University of Nevada at Reno (UNR)

Shireen Rizvi, PhD principal investigator

Rutgers University

4 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 19 Aug 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Suicide Ideation - Phase 1 (time frame: Baseline to the end of Phase 1 treatment (up to 6 weeks)). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04707066, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Aug 2026.